Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lenalidomid, ATC L04AX04 für die Zeit 01.07.2025 - 30.06.2027 (zzgl. Verlängerungsoption 1x12 Monate)

Worth a closer look

• § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be borne by the statutory health insurance funds.
• The DAK-Gesundheit intends to conclude discount agreements with as many interested pharmaceutical companies as possible until new medicinal product discount agreements come into force.
• The procedure is not considered to fall within the scope of cartel procurement law due to the lack of a selection decision and the resulting non-discriminatory access for all pharmaceutical companies.
• The contract documents are available for download via the online portal www.dtvp.de/center.
• The offer is to be submitted in text form as an electronic offer via email.
• The publication is made using the form for open procedures, although this is not a formal open procedure due to technical reasons.